vs

Side-by-side financial comparison of Legence Corp. (LGN) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.

Legence Corp. is the larger business by last-quarter revenue ($708.0M vs $493.8M, roughly 1.4× Pediatrix Medical Group, Inc.). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs -0.1%, a 6.9% gap on every dollar of revenue. On growth, Legence Corp. posted the faster year-over-year revenue change (26.2% vs -1.7%).

Legence Corp is a leading sustainable building and decarbonization solution provider. It delivers energy efficiency optimization, building automation design, renewable energy integration, and low-carbon retrofit services for commercial, industrial, and institutional clients, with core operations across North America to help customers cut costs and reduce carbon footprints.

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

LGN vs MD — Head-to-Head

Bigger by revenue
LGN
LGN
1.4× larger
LGN
$708.0M
$493.8M
MD
Growing faster (revenue YoY)
LGN
LGN
+28.0% gap
LGN
26.2%
-1.7%
MD
Higher net margin
MD
MD
6.9% more per $
MD
6.8%
-0.1%
LGN

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LGN
LGN
MD
MD
Revenue
$708.0M
$493.8M
Net Profit
$-576.0K
$33.7M
Gross Margin
20.9%
Operating Margin
5.3%
9.9%
Net Margin
-0.1%
6.8%
Revenue YoY
26.2%
-1.7%
Net Profit YoY
46.8%
10.5%
EPS (diluted)
$-0.02
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LGN
LGN
MD
MD
Q4 25
$493.8M
Q3 25
$708.0M
$492.9M
Q2 25
$468.8M
Q1 25
$458.4M
Q4 24
$502.4M
Q3 24
$560.8M
$511.2M
Q2 24
$504.3M
Q1 24
$495.1M
Net Profit
LGN
LGN
MD
MD
Q4 25
$33.7M
Q3 25
$-576.0K
$71.7M
Q2 25
$39.3M
Q1 25
$20.7M
Q4 24
$30.5M
Q3 24
$-1.1M
$19.4M
Q2 24
$-153.0M
Q1 24
$4.0M
Gross Margin
LGN
LGN
MD
MD
Q4 25
Q3 25
20.9%
Q2 25
Q1 25
Q4 24
Q3 24
21.1%
Q2 24
Q1 24
Operating Margin
LGN
LGN
MD
MD
Q4 25
9.9%
Q3 25
5.3%
13.8%
Q2 25
12.8%
Q1 25
7.0%
Q4 24
7.8%
Q3 24
4.8%
6.6%
Q2 24
-31.3%
Q1 24
3.2%
Net Margin
LGN
LGN
MD
MD
Q4 25
6.8%
Q3 25
-0.1%
14.5%
Q2 25
8.4%
Q1 25
4.5%
Q4 24
6.1%
Q3 24
-0.2%
3.8%
Q2 24
-30.3%
Q1 24
0.8%
EPS (diluted)
LGN
LGN
MD
MD
Q4 25
$0.40
Q3 25
$-0.02
$0.84
Q2 25
$0.46
Q1 25
$0.24
Q4 24
$0.37
Q3 24
$0.23
Q2 24
$-1.84
Q1 24
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LGN
LGN
MD
MD
Cash + ST InvestmentsLiquidity on hand
$176.0M
$375.2M
Total DebtLower is stronger
$812.6M
$570.5M
Stockholders' EquityBook value
$387.9M
$865.9M
Total Assets
$2.6B
$2.2B
Debt / EquityLower = less leverage
2.10×
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LGN
LGN
MD
MD
Q4 25
$375.2M
Q3 25
$176.0M
$340.1M
Q2 25
$224.7M
Q1 25
$99.0M
Q4 24
$229.9M
Q3 24
$103.8M
Q2 24
$19.4M
Q1 24
$8.0M
Total Debt
LGN
LGN
MD
MD
Q4 25
$570.5M
Q3 25
$812.6M
$577.2M
Q2 25
$583.9M
Q1 25
$590.5M
Q4 24
$597.1M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
LGN
LGN
MD
MD
Q4 25
$865.9M
Q3 25
$387.9M
$890.7M
Q2 25
$833.8M
Q1 25
$789.2M
Q4 24
$764.9M
Q3 24
$732.5M
Q2 24
$706.5M
Q1 24
$856.2M
Total Assets
LGN
LGN
MD
MD
Q4 25
$2.2B
Q3 25
$2.6B
$2.2B
Q2 25
$2.1B
Q1 25
$2.0B
Q4 24
$2.2B
Q3 24
$2.1B
Q2 24
$2.0B
Q1 24
$2.2B
Debt / Equity
LGN
LGN
MD
MD
Q4 25
0.66×
Q3 25
2.10×
0.65×
Q2 25
0.70×
Q1 25
0.75×
Q4 24
0.78×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LGN
LGN
MD
MD
Operating Cash FlowLast quarter
$162.1M
$114.1M
Free Cash FlowOCF − Capex
$137.4M
FCF MarginFCF / Revenue
19.4%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
3.39×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LGN
LGN
MD
MD
Q4 25
$114.1M
Q3 25
$162.1M
$137.3M
Q2 25
$137.2M
Q1 25
$-117.5M
Q4 24
$133.0M
Q3 24
$91.8M
Q2 24
$107.0M
Q1 24
$-125.2M
Free Cash Flow
LGN
LGN
MD
MD
Q4 25
Q3 25
$137.4M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
LGN
LGN
MD
MD
Q4 25
Q3 25
19.4%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
LGN
LGN
MD
MD
Q4 25
Q3 25
3.5%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
LGN
LGN
MD
MD
Q4 25
3.39×
Q3 25
1.91×
Q2 25
3.49×
Q1 25
-5.66×
Q4 24
4.36×
Q3 24
4.72×
Q2 24
Q1 24
-31.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LGN
LGN

Installation And Fabrication$408.7M58%
Engineering And Design$110.9M16%
Program And Project Management$101.2M14%
Maintenance And Service$87.1M12%

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

Related Comparisons